Cargando…

In vitro inhibitory activity of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 alone or in combination against bacterial and Candida reference strains and clinical isolates

Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 are two strains frequently used as probiotic components in food supplements. The decrease of potentially pathogenic gastrointestinal microorganisms is one of their claimed mechanisms. The aim of this study was to investigate their abilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Inturri, Rosanna, Trovato, Laura, Volti, Giovanni Li, Oliveri, Salvatore, Blandino, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881622/
https://www.ncbi.nlm.nih.gov/pubmed/31799467
http://dx.doi.org/10.1016/j.heliyon.2019.e02891
_version_ 1783473982232592384
author Inturri, Rosanna
Trovato, Laura
Volti, Giovanni Li
Oliveri, Salvatore
Blandino, Giovanna
author_facet Inturri, Rosanna
Trovato, Laura
Volti, Giovanni Li
Oliveri, Salvatore
Blandino, Giovanna
author_sort Inturri, Rosanna
collection PubMed
description Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 are two strains frequently used as probiotic components in food supplements. The decrease of potentially pathogenic gastrointestinal microorganisms is one of their claimed mechanisms. The aim of this study was to investigate their ability, alone or in combination, to inhibit in vitro the growth of Gram-negative, Gram-positive and Candida reference strains and clinical isolates, using different methods. The cell-free supernatants were obtained by centrifugation and filtration from single or mixed broth cultures and the inhibitory activity was tested using both agar-well diffusion and broth microdilution methods. In order to get some preliminary information about the chemical nature of the active metabolites released in the supernatants, the inhibitory activity was investigated after neutralization, heat and proteolytic treatments. The highest inhibitory activity was shown by the untreated supernatant obtained from broth culture of the two probiotic strains, especially against bacterial reference strains and clinical isolates. This supernatant showed inhibitory activity towards Candida species, too. A decreased inhibitory activity was observed for the supernatants obtained from single cultures and after proteolytic treatment, against bacterial reference strains. The study suggests that the combination of B. longum BB536 and L. rhamnosus HN001 could represent a possible alternative against gastrointestinal and urinary pathogens either as prophylaxis or as treatment.
format Online
Article
Text
id pubmed-6881622
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-68816222019-12-03 In vitro inhibitory activity of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 alone or in combination against bacterial and Candida reference strains and clinical isolates Inturri, Rosanna Trovato, Laura Volti, Giovanni Li Oliveri, Salvatore Blandino, Giovanna Heliyon Article Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 are two strains frequently used as probiotic components in food supplements. The decrease of potentially pathogenic gastrointestinal microorganisms is one of their claimed mechanisms. The aim of this study was to investigate their ability, alone or in combination, to inhibit in vitro the growth of Gram-negative, Gram-positive and Candida reference strains and clinical isolates, using different methods. The cell-free supernatants were obtained by centrifugation and filtration from single or mixed broth cultures and the inhibitory activity was tested using both agar-well diffusion and broth microdilution methods. In order to get some preliminary information about the chemical nature of the active metabolites released in the supernatants, the inhibitory activity was investigated after neutralization, heat and proteolytic treatments. The highest inhibitory activity was shown by the untreated supernatant obtained from broth culture of the two probiotic strains, especially against bacterial reference strains and clinical isolates. This supernatant showed inhibitory activity towards Candida species, too. A decreased inhibitory activity was observed for the supernatants obtained from single cultures and after proteolytic treatment, against bacterial reference strains. The study suggests that the combination of B. longum BB536 and L. rhamnosus HN001 could represent a possible alternative against gastrointestinal and urinary pathogens either as prophylaxis or as treatment. Elsevier 2019-11-22 /pmc/articles/PMC6881622/ /pubmed/31799467 http://dx.doi.org/10.1016/j.heliyon.2019.e02891 Text en © 2019 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Inturri, Rosanna
Trovato, Laura
Volti, Giovanni Li
Oliveri, Salvatore
Blandino, Giovanna
In vitro inhibitory activity of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 alone or in combination against bacterial and Candida reference strains and clinical isolates
title In vitro inhibitory activity of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 alone or in combination against bacterial and Candida reference strains and clinical isolates
title_full In vitro inhibitory activity of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 alone or in combination against bacterial and Candida reference strains and clinical isolates
title_fullStr In vitro inhibitory activity of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 alone or in combination against bacterial and Candida reference strains and clinical isolates
title_full_unstemmed In vitro inhibitory activity of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 alone or in combination against bacterial and Candida reference strains and clinical isolates
title_short In vitro inhibitory activity of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 alone or in combination against bacterial and Candida reference strains and clinical isolates
title_sort in vitro inhibitory activity of bifidobacterium longum bb536 and lactobacillus rhamnosus hn001 alone or in combination against bacterial and candida reference strains and clinical isolates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881622/
https://www.ncbi.nlm.nih.gov/pubmed/31799467
http://dx.doi.org/10.1016/j.heliyon.2019.e02891
work_keys_str_mv AT inturrirosanna invitroinhibitoryactivityofbifidobacteriumlongumbb536andlactobacillusrhamnosushn001aloneorincombinationagainstbacterialandcandidareferencestrainsandclinicalisolates
AT trovatolaura invitroinhibitoryactivityofbifidobacteriumlongumbb536andlactobacillusrhamnosushn001aloneorincombinationagainstbacterialandcandidareferencestrainsandclinicalisolates
AT voltigiovannili invitroinhibitoryactivityofbifidobacteriumlongumbb536andlactobacillusrhamnosushn001aloneorincombinationagainstbacterialandcandidareferencestrainsandclinicalisolates
AT oliverisalvatore invitroinhibitoryactivityofbifidobacteriumlongumbb536andlactobacillusrhamnosushn001aloneorincombinationagainstbacterialandcandidareferencestrainsandclinicalisolates
AT blandinogiovanna invitroinhibitoryactivityofbifidobacteriumlongumbb536andlactobacillusrhamnosushn001aloneorincombinationagainstbacterialandcandidareferencestrainsandclinicalisolates